Dexcel Pharma has co-led a $60m series A round for Immunai, which previously collected $20m in seed financing less than a year ago.
US-based immunotherapy developer Immunai received $60m in a series A round on Thursday co-led by speciality pharmaceutical firm Dexcel Pharma.
Schusterman Family Investments, Duquesne Family Office and Catalio Capital Management co-led the round, which also attracted Viola Ventures and TLV Partners.
Founded in 2018, Immunai’s technology combines high-resolution single-cell analytics with machine learning to uncover insights into the regulation and function of the immune system to make immunotherapies more effective. It collects the data in a proprietary database called Amica.
…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
